TABLE 2.
Number of positive samples among anti-HCV Ab-negative samples included in panel 2, according to the assay
| Patient no. | Genotypeb | No. of samples tested (n = 83) | No. of samplesc: |
|||
|---|---|---|---|---|---|---|
| RNA HCV positive | HCV core Ag blood screening assay positive | trak-C assay positive | Monolisa HCV Ag/Ab ULTRA positivea | |||
| S9 | 1b | 3 | 2 | 2 | 2 | 0 |
| S10 | 1b | 2 | 1 | 1 | 1 | 1 |
| S11 | nt | 7 | 6 | 3 | 6 | 0 |
| S12 | 1b | 2 | 1 | 1 | 1 | 1 |
| S13 | 3a | 1 | 0 | 0 | 0 | 0 |
| S14 | 1a | 3 | 2 | 2 | 2 | 2 |
| S16 | 1b | 1 | 0 | 0 | 0 | 0 |
| S17 | 1b | 11 | 10 | 6/6 | 9/9 | 6 |
| S18 | 1b | 3 | 2 | 1 | 2 | 0 |
| S19 | 1 | 5 | 5 | 3 | 4 | 0 |
| S20 | 1b | 1 | 0 | 0 | 0 | 0 |
| S21 | 2a/2c | 3 | 2 | 2 | 2 | 1 |
| S23 | 1b | 2 | 1 | 0 | 1 | 0 |
| S24 | 3a | 5 | 4 | 4 | 4 | 3 |
| S29 | 1b | 4 | 2 | 2 | 2 | 2 |
| S31 | 4c/4d | 2 | 1 | 1 | 1 | 0 |
| R1 | 2a/2c | 7 | 5 | 4 | 4 | 3 |
| R2 | 2a/2c | 6 | 5 | 0 | 3/3 | 0 |
| R5 | 2a/2c | 3 | 1 | 0 | 1 | 0 |
| R6 | 2a/2c | 4 | 4 | 3 | 3/3 | 2 |
| R7 | 2a/2c | 3 | 2 | 1/1 | 2 | 2 |
| R8 | 2a/2c | 1 | 0 | 0 | 0 | 0 |
| R9 | 2a/2c | 4 | 3 | 3 | 2/2 | 0 |
| No. positive/no. of HCV RNA-positive samples tested (%) | 59/59 (100) | 39/54 (72.2) | 52/54 (96.3) | 23/59 (39) | ||
a
Including four samples in the gray zone.
b
nt, nontypeable.
c
Where not all samples were tested, values are numbers of positive samples/numbers tested.